EQS-Adhoc: Pentixapharm Holding AG: Pentixapharm significantly reduces projected loss for financial year 2025

Ad-hoc Disclosure of Inside Information Pursuant to Article 17 Regulation (EU)
No. 596/2014

Pentixapharm significantly reduces projected loss for financial year 2025

Berlin, Germany, November 6, 2025 – Pentixapharm Holding AG (Frankfurt Prime Standard: PTP), an advanced clinical-stage biotech developing radiopharmaceuticals, announces that its projected consolidated loss for the financial year 2025, based on an updated projection, will be significantly lower than previously anticipated.

The company now forecasts an annual loss of approximately €18 million instead of the previously expected €23.5 million. The forecasts for the separate financial statements of Pentixapharm Holding AG as well as the expected cash reach until the first quarter of 2027 remain unchanged.

The revised forecast reflects the realignment of the clinical development programs initiated in May 2025. In particular, the earlier-than-planned termination of the slow-recruiting diagnostic study in marginal zone lymphoma and optimized study design have lowered clinical spending more significantly than initially expected. With the sharpened focus on the clinically most value driving programs implemented in October 2025, the company is continuing to execute on its optimization course.

 About Pentixapharm

Pentixapharm is an advanced clinical-stage biotech expanding the boundaries of radiopharmaceuticals. Headquartered in Berlin, Germany, the company develops precision diagnostics and therapeutics in oncology and cardiology to transform patient care. Its clinical pipeline is anchored by CXCR4-targeted PET-CT programs, including a Phase 3-ready candidate for the improved diagnosis of hypertensive patients with primary aldosteronism, which is intended to enable targeted treatment of the underlying causes of hypertension. CXCR4-based developments also include pioneering therapeutic programs in hematological cancers. Furthermore, Pentixapharm is advancing a next-generation antibody platform targeting CD24, an emerging immune-checkpoint marker over-expressed in multiple hard-to-treat cancers. Complemented by CXCR4 and CD24 intellectual property protection and a reliable isotope supply chain, Pentixapharm is poised to deliver meaningful patient benefit and sustainable growth in one of the fastest-growing areas of precision medicine.

Pentixapharm Investor and Media Contact

ir@pentixapharm.com